Piaoyang Sun, PhD.
Chairman of Jiangsu Hengrui Medicine Co., Ltd
Dr. Piaoyang Sun is Chairman of the Board of Jiangsu Hengrui Medicine Co., Ltd. Outside Hengrui, he also serves as adjunct professor at China Pharmaceutical University, member of the 8th, 9th and 10th Chinese Pharmacopoeia Commission, vice-chairman of Jiangsu Association for Science and Technology, vice-chairman of Jiangsu Federation of Industry and Commerce, and multiple other academic and social service positions.
Dr. Sun has decades of leadership experience in pharmaceutical R&D and management. As the founder and leader of Hengrui, he has led the company’s major drive towards innovation and globalization. Under his leadership, Hengrui’s team launched two Class 1.1 innovative drugs Imrecoxib and Apatinib in the past six years, and a number of innovative drug are now undergoing clinical studies in the US. Hengrui is currently leading in antibody drug conjugate (ADC), immunotherapy and multiple other categories/disease areas in China. In 2015, Hengrui successfully out-licensed its investigational anti-PD-1 monoclonal antibody to the US biotech company Incyte and in-licensed an antiemetic drug, rolapitant from Tesaro for China. In addition, in recent years, Hengrui has marketed multiple products including Injectables in the US and EU, making it the only Chinese pharmaceutical company attaining this achievement. His vision and focus on innovation and quality has not only transformed Hengrui, but also impacted and influenced the entire Chinese pharmaceutical industry.
Dr. Sun earned a bachelor’s degree in Medicinal Chemistry from China Pharmaceutical University and obtained his doctorate in Organic Chemistry from Nanjing University.
Lianshan Zhang, PhD.
Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine Co., Ltd.
Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. In 2010, Dr. Zhang joined Hengrui and is responsible for R&D strategy and management of all the NMEs across the globe. Prior to Hengrui, he was a senior director of chemistry at Marcadia Biotech. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide/protein therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.
Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. (summa cum laude) in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University.
Sean Zhang, MD, FCP
Site Head, Chief Medical Officer
Dr. Sean Zhang is a well accredited Physician-Scientist with more than 30 years’ experience in medical practice, academic research, drug discovery and development. He has ~20-years of pharmaceutical industry work experience in global leading pharmaceutical companies such as Merck, Johnson & Johnson, Bristol-Myers Squibb and GlaxoSmithKline with increasing responsibilities. His extensive experience spans the entire drug discovery, clinical development and life cycle management process.
Before coming to the United States, Dr. Zhang was a Staff Physician and Clinical Investigator in the Chinese Military General (301) Hospital in Beijing, China with a focus on the early diagnosis and treatment of gastrointestinal and liver cancers. He completed his clinical fellowship training program in Clinical Pharmacology at the Clinical Center of National Institute of Health after passing the United States Medical License Examination. Dr. Zhang is a Fellow of American College of Clinical Pharmacology (FCP), and a board member of the Sino-American Pharmaceutical Professional Association (SAPA), an organization with more than five thousand Chinese American pharmaceutical professionals. He has authored more than 30 peer-reviewed publications and is a frequent speaker at multiple national/international conferences/symposiums on translational medicine and early drug development.